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Introduction
The goals of the AACR Special Conference on Advances
in Breast Cancer Research, organized by Carlos Arteaga
(Vanderbilt University, Nashville, TN, USA) and Lewis
Chodosh (University of Pennslyvania, Philadelphia, PA,
USA), were to put forward the latest discoveries relevant
to mammary development, transformation, breast cancer
progression, and promising avenues of treatment. Approxi-
mately 225 people attended the conference from various
academic research institutions and pharmaceutical com-
panies in the United States and across the world. In addi-
tion to presentations given by speakers in the topics
detailed below, there were approximately 100 poster pre-
sentations in two evening sessions. The keynote lecture,
given by Philip Leder (Harvard Medical School, Boston,
MA, USA), set the tone for the conference by providing a
motivational presentation beginning with the impact of
breast cancer on our society. He provided an overview of
where the field stands, with special attention given to the
utility of mouse models to address factors that may coop-
erate in breast tumorigenesis. In the second part of the
talk, Dr Leder reviewed some of the work by his laboratory
involving screens to identify small molecules that selec-
tively inhibit growth of breast tumor cells. Lastly, he left us
with a challenge: to understand some of the mechanisms
behind the clinical observation that pregnancy before the
age of 19 lowers one’s risk of developing breast cancer. Is
there a safe way to mimic pregnancy with hormonal treat-
ment, for example, to reduce risk of breast cancer later in
life? To test this, we will have to develop better models to
study the phenomenon; the most popular promoters used
to drive mammary-specific expression of transgenes (i.e.
mouse mammary tumor virus [MMTV]) are highly respon-
sive to hormones.
Mammary stem cells and development
The existence of mammary stem and progenitor cells has
been established by a number of groups on the basis of
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Abstract
The recent meeting ‘Advances in Breast Cancer Research — Genetics, Biology, and Clinical
Implications’ was an American Association for Cancer Research (AACR) Special Conference in
Cancer Research, for which the underwriting sponsor was the Avon Foundation. Presentations were
made from prominent scientists on several relevant basic science and clinic-oriented topics, including
mammary stem cells and development, steroid receptors, matrix and stromal–epithelial interactions,
oncogene signaling and imaging, genetics and prevention, and molecular therapeutics. A summary of
recent findings is presented here, with a particular emphasis on unpublished work.
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morphology (as viewed by electron microscopy), function
(by serial transplantation of mammary glands or mammary
epithelial cells at limiting dilutions), and as distinct, trans-
plantable populations in the mammary gland (by the isola-
tion of cells with flow cytometry as either a ‘side
population’ on the basis of their ability to exclude Hoechst
dye, or by expression of cell-surface markers such as
Sca-1). Gilbert Smith (National Cancer Institute,
Bethesda, MD, USA) reviewed his early work on the char-
acterization of different cell populations in the mammary
gland by electron microscopy and limited-dilution trans-
plantations. He also described experiments defining the
presence of bipotential progenitor cells in pregnant and
lactating glands that, even after involution, can contribute
to the gland in the next pregnancy. Jeffrey Rosen (Baylor
College of Medicine, Houston, TX, USA) expanded on his
laboratory’s characterization of mammary epithelial cell lin-
eages in the normal gland and in breast cancer. Dr Rosen
described developmental data supporting a paracrine
model of signaling to regulate proliferation in the mammary
gland: cells expressing progesterone receptor (PR+ cells)
(which are not themselves proliferating) may secrete
factors such as Wnt that can induce neighboring cells to
proliferate. He noted that in ductal carcinoma in situ, PR+
cells are proliferating, indicating a possible disruption of
the paracrine signaling pathway during tumor develop-
ment. Dr Rosen suggested that, in light of recent data
implicating Wnt signaling in expansion of a progenitor-like
tumor, progenitor cells may be susceptible to transforma-
tion. This could account for some of the genetic and clini-
cal heterogeneity in breast cancer, as well as explain some
recurrences after treatment has eradicated the tumor
mass (a long-standing idea that is becoming more com-
pelling in light of recent evidence).
John Wysolmerski (Yale University School of Medicine,
New Haven, CT, USA) presented data regarding the role
of Wnt signaling in embryonic mammary gland develop-
ment. Using TOPGAL (Wnt-responsive) reporter mice, Dr
Wysolmerski showed that Wnt activity increases during
mammary bud formation and then decreases until the first
wave of branching morphogenesis. Although several Wnt
genes are expressed in mammary placodes, exogenous
Wnt-3a expression in embryo cultures is sufficient to
cause premature formation of placodes. Further, tetracy-
cline-regulated expression of the Wnt inhibitor dickkopf1
(Dkk1) inhibits placode formation and the production of
placode markers such as β-catenin, Tbx3, and Wnt-10b.
Hence it appears that wnt, which is a proven oncogene in
the mammary gland, not only plays a pivotal role in
mammary gland development, but also may contribute to
maintaining a progenitor-like state in tumors.
Steroid receptors
Orla Conneely (Baylor College of Medicine) echoed Philip
Leder’s sentiments about the importance of understanding
why early pregnancy is protective for breast cancer. Her
work has previously shown that PRB (progesterone recep-
tor, B isoform) is required for normal proliferation and sur-
vival of mammary epithelium, and that this is at least in part
due to production of the receptor activator of nuclear
factor κB (NFκB) ligand (RANKL) in PR+ cells. This ligand,
in turn, may act on neighboring cells to induce proliferation
downstream of NFκB-mediated expression of cyclin D1.
This also supports the notion that misexpression of PR
may disrupt paracrine control of proliferation. In further
support of this idea, the expression of PR in proliferating
cells after carcinogenesis is prevented by early exposure
to estrogen and progesterone.
Myles Brown (Dana-Farber Cancer Institute, Boston, MA,
USA) spoke about modulators of steroid receptor action,
and anti-estrogen therapies in particular. Selective estro-
gen receptor modulators, such as tamoxifen and ralox-
ifene, generally function in mammary tissue by binding to
estrogen receptor (ER) and recruiting corepressors to
target promoters. Dr Brown’s group is addressing whether
aberrant coactivator expression or recruitment could
account for resistance to tamoxifen in some breast
cancers. Chromatin immunoprecipitation assays showed
that while both tamoxifen and raloxifene recruit ER to
target promoters, tamoxifen treatment led to the recruit-
ment of several coactivators, including SRC (steroid
receptor coactivator), AIB-1 (amplified in breast cancer-1),
and cyclic AMP response element binding protein
(CREB). Raloxifene, on the other hand, only caused
recruitment of corepressors. Overexpression of AIB-1 in
the mammary gland resulted in a larger gland, increased
proliferation, precocious lobular differentiation, delayed
involution, and decreased apoptosis. The mice formed
mammary tumors with a latency of 12–18 months;
however, reproductive history had no effect on tumor for-
mation or latency. In a related presentation, Donald
McDonnell (Duke University Medical Center, Durham, NC,
USA) reported that the environmental toxicant methoxy-
acetic acid (MAA), which is found in paints, varnishes, and
fuels, enhances tamoxifen-induced ER-mediated transcrip-
tional activity. These data are relevant because exposure
to MAA increases the risk for breast cancer in humans.
MAA stimulates the MAPK (mitogen-activated protein
kinase) pathway, which was also implicated in ER function
by Ellis Levin (Long Beach VA Medical Center, Long
Beach, CA, USA), who supported the notion that mem-
brane-bound ER may signal through this pathway to acti-
vate nuclear ER.
The function of ER in proliferation was addressed by Peter
Kushner (University of California, San Francisco, CA,
USA). ERα can activate two types of target genes: it can
act as a direct activator of promoters that contain estro-
gen response element (ERE) sites (example targets
include prolactin and PR), and it can act as a coactivator3
for Jun/ATF at promoters that contain cAMP response
element (CRE) sites (of which cyclin D1 is a target). Dr
Kushner presented elegant work with a mutant of ERα,
K206A, which is a superactivator at promoters containing
activator protein 1 (AP1) or CRE promoters but retains
normal activation at ERE-containing promoters. Mice that
overexpress ERαK206A under the MMTV promoter
display exaggerated mammary gland development and
increased lobular development upon stimulation with
estrogen. Expression of ERαK206A under either MMTV or
keratin-14 promoters resulted in hyperplasia of the
mammary gland; neither MMTV-driven nor keratin-14-
driven wild-type ER had this phenotype. A low incidence
of mammary tumors was also reported in mice expressing
ERαK206A.
Matrix and stromal–epithelial interactions
To start the session, David Cheresh (The Scripps Institute,
La Jolla, CA, USA) reviewed some of his recently pub-
lished work, which revealed Raf1 as a common target of
vascular endothelial growth factor (VEGF)- and fibroblast
growth factor (FGF)-induced survival signals in angiogene-
sis. The specificity of these pathways is derived from
phosphorylation of Raf1 on adjacent sites; VEGF-depen-
dent phosphorylation is dependent on p21-activated
kinase 1 (PAK1), and FGF-dependent phosphorylation is
dependent on Src kinase. Delivery of mutant Raf1-contain-
ing nanoparticles caused apoptosis in tumor-associated
vessels as well as death in the surrounding tumor; this is
attributed to bystander effect. The role of PAK in cell
migration was addressed by Rudolph Juliano (University of
North Carolina, Chapel Hill, NC, USA). Dr Juliano pre-
sented data demonstrating that nischarin, a recently
described protein that interacts with integrins and inhibits
cell migration, binds to and inhibits PAK. He proposed
that upon binding of extracellular matrix, nischarin disasso-
ciates from the integrin complex, allowing cell migration via
activation of Rac and PAK.
Valerie Weaver (University of Pennsylvania) presented
exciting new data regarding the ligation of β integrins in
response to the rigidity of the microenvironment. In three-
dimensional cultures consisting of reconstituted basement
membrane, cells are in a more compliant microenviron-
ment than when in two-dimensional culture. Dr Weaver
showed reduced activation of β1 integrin pathways in
three-dimensional cultures, which she found to increase
as the tension of the surrounding extracellular matrix was
experimentally increased. These data not only emphasize
the importance of the culture microenvironment in inter-
preting experimental studies, but also have implications for
altered integrin signaling in tumors, which have higher
tension due to increased collagen deposition.
Harold Moses (Vanderbilt-Ingram Cancer Center,
Nashville, TN, USA) addressed the role of transforming
growth factor β (TGFβ) signaling in enhancing tumor pro-
gression and metastasis of several mouse mammary tumor
models. Dr Moses presented elegant new data involving
deletion of the type II TGFβ receptor (βIIR) in fibroblasts.
When fibroblasts lacking this receptor were mixed with a
tumorigenic cell line expressing the polyomavirus middle T
antigen (PyMT) and grafted into renal capsules, the result-
ing tumors were approximately 2.5 times as large as those
reconstituted with wild-type fibroblasts. These data
support a positive role for TGFβ signaling in tumors via a
paracrine mechanism.
Oncogene signaling and imaging
As a result of continuing development of new tools and
model systems in which to study breast cancer, there has
been significant progress in understanding mechanisms of
tumorigenesis, cell invasion, and metastasis. Joan Brugge
(Harvard Medical School) presented work from her labora-
tory pertaining to the reconstruction of tumor phenotypes
with MCF10A cells in three-dimensional cultures using
retroviral delivery of oncogenes. Using this powerful
method, they have been able to identify genes that induce
hyperplasia (for example, the genes for ErbB2, colony
stimulating factor 1, colony stimulating factor receptor,
insulin-like growth factor 1, insulin-like growth factor
receptor, c-Met, and hepatocyte growth factor), a more
intermediate phenotype (for example, Wnt-1, intracellular
notch, activated Akt), and combinations of genes whose
proteins induce an invasive phenotype (for example,
ErbB2 + TGFβ). Her laboratory is currently making
progress on the mechanisms involved in the various tumor
phenotypes.
William Muller (McGill University, Montreal, Canada) also
addressed mechanisms of tumor formation and invasion.
Using elegant mouse genetics, he demonstrated that
some target(s) of phosphatidylinositol 3-kinase, other than
Akt, are required for pulmonary metastasis of
MMTV–PyMT tumors. In another system, he showed that
β1 integrin is critical for progression of MMTV–PyMT
tumorigenesis. Lewis Chodosh (University of Pennsylva-
nia) and his group are utilizing mammary-specific, doxycy-
cline-inducible mouse models to characterize not only the
fine points of tumor progression, but also whether tumors
remain dependent on the initiating event. As he has shown
in recent publications, several factors can influence tumor
regression and recurrence: mutations in K-ras can render
Myc-induced tumors resistant to reversal, and loss of one
allele of p53 can contribute to recurrence of Wnt-induced
tumors. Dr Chodosh also presented interesting data sug-
gesting that, once regressed, residual neoplastic disease
can remain dormant for some time; reinduction of the
oncogene leads to tumor formation at a much faster rate
than was seen with formation of the initial tumor. The
theme of dissecting molecular pathways that contribute to
tumorigenesis was continued by Peter Sicinski (Dana-
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Farber Cancer Institute), who presented recently pub-
lished work from his laboratory on the phenotype of cyclin
E1/E2 double-knockout animals. Future work on the
requirement for these cyclins in progression of mammary
tumors is greatly anticipated.
Lastly, there was some discussion on methods to image
tumor progression. Ronald Blasberg (Memorial Sloan-Ket-
tering Cancer Center, New York, NY, USA) gave an
overview of methods of noninvasive imaging, with a partic-
ular emphasis on reporter imaging. His laboratory has
used various imaging systems to dissect several endoge-
nous molecular pathways, including activation of hypoxia-
inducible factor α in xenografts using a hypoxia-responsive
promoter that drives expression of green fluorescent
protein.
Genetics and prevention
Thea Tlsty (University of California, San Francisco) started
off this session with a comprehensive talk covering early
genetic and epigenetic events in human breast cancer.
Using an in vitro model system to identify human
mammary epithelial cell ‘variants’ that escape normal pro-
liferation barriers, Dr Tlsty’s group has identified a number
of early events in breast cancer, including chromosomal
abnormalities such as telomeric association, abnormal
centrosome numbers, and hypermethylation of the p16
promoter. Importantly, overexpression of wild-type p16 in
these variants can induce a senescent-like phenotype, and
‘knocking down’ p16 expression with siRNA (small inter-
fering RNA) in normal cells leads to abnormal centrosome
numbers through a failure to couple centrosome duplica-
tion with the cell cycle. These data support a critical role
for p16 in genomic stability of breast epithelial cells.
Michael Kastan (Saint Jude Children’s Research Hospital,
Memphis, TN, USA) reminded us that cancer susceptibility
is often linked to responses to DNA damage. His labora-
tory has found that breaks in DNA, which cause relaxation
of tightly wound chromatin, may be an important signal for
activation of ataxia-telangiectasia-mutated kinase to initiate
the cellular response to DNA damage. The topic of DNA
repair was continued by Alan D’Andrea (Dana-Farber
Cancer Institute), who reviewed details regarding cooper-
ation between the Fanconi anemia DNA damage repair
complexes and BRCA1/2. He also showed that ATR
(ataxia-telangiectasia and Rad3-related protein), mutations
of which lead to Seckel syndrome, may be a sensor kinase
to turn on the Fanconi/BRCA DNA damage pathway. To
wrap up the session, David Livingston (Dana-Farber
Cancer Institute) demonstrated specific localization of
BRCA1 at sites of DNA damage. This localization requires
the C-terminus of the BRCA1 protein, and proper localiza-
tion of BRCA2 is dependent on BRCA1. Dr Livingston
also presented data building on his previous report of
interaction of BRCA1 with RNA of Xi-specific transcripts
on the inactive X chromosome. He showed intriguing data
that the presence of RNA could also affect colocalization
of BRCA1 with pericentromeric heterochromatin after
DNA damage. These data lead one to speculate whether
interaction with RNA might contribute to the DNA repair
function of BRCA1.
Molecular therapeutics
Carlos Arteaga (Vanderbilt University) presented data
from his laboratory addressing mechanisms of the putative
switch of TGFβ from tumor suppressor to tumor promoter.
He showed that very low levels of TGFβ receptor activa-
tion induce effects independent of Smad (the human
homologue of Sma and MAD proteins), including activa-
tion of Akt and Erk kinases. In vivo, TGFβ activation in
MMTV-neu mice results in less differentiated, more inva-
sive tumors. Treatment of tumor explants in matrigel with
TGFβ inhibitors such as LY580276 reverts the invasive
behavior and induces apoptosis. Together, these data
provide evidence of the potential efficacy of TGFβ
inhibitors in disrupting both tumor maintenance and
metastasis.
Powel Brown (Baylor College of Medicine) addressed the
need for therapeutics for ER– breast cancer. Dr Brown
presented data showing that ZD1839 (Iressa), a selective
inhibitor of epidermal growth factor receptor–tyrosine
kinase, can reduce proliferation of xenografts of human
ductal carcinoma in situ in mice. Additionally, both Iressa
and retinoids can suppress development of ER– (MMTV-
neu) tumors in mice when administered chronically. These
data, and others, have led to a current clinical trial on the
efficacy of the retinoid LGD1069, which is selective for
retinoid-X receptor, in preventing the disease in women at
high risk.
C Kent Osborne (Baylor College of Medicine) provided an
overview of the latest clinical findings that aromatase
inhibitors are beneficial after treatment with selective
estrogen receptor modulators in ER+ breast cancer. He
expanded on mechanisms for hormonal resistance and his
recent data suggesting that resistance to tamixofen corre-
lates with high levels of both AIB1 and HER2 (human c-
ErbB2) overexpression. In xenograft studies, inhibition of
both ER and growth factor signaling (with tamixofen and
Iressa) is more effective than inhibiting either pathway
alone.
Lastly, Keith Knutson (University of Washington, Seattle,
WA, USA) showed that immunization of animals with Neu
intracellular domain peptides before exposure to Neu-
expressing tumors acutely reduced tumor growth. Stage III
and IV clinical trials, in which patients were vaccinated
once per month for 6 months with HER2/Neu vaccines,
showed no toxicity. Other results from the study showed
that the majority of patients developed ‘epitope spread-
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ing’, or a broadening of the immune response, and immu-
nity persisted for at least 1 year in half of the patients.
Barriers and motivators to breast cancer
screening
Despite constant advances in our understanding of the
molecular basis of breast cancer and the generation of
more effective therapeutics, a critical component of the
outcome of the disease is early detection. Marydale DeBor
(lawyer and senior consultant for the Avon Foundation)
reported that the Avon Foundation is the largest private
contributor to breast cancer research; it has raised more
than $250 million over the past 10 years for basic and
translational research, as well as issues directly pertaining
to patient care. Barbara Cicatelli (Avon Foundation Breast
Care Fund, New York, NY, USA) presented an enlighten-
ing study of more than 100,000 women to determine the
major barriers to breast cancer screening, from both
patients’ and caregivers’ perspectives. Interestingly, while
patients most often described barriers such as personal
belief (the view that one’s health is in God’s hands) and a
lack of perceived risk, heath care providers thought that
the major barriers were based on fear or were financial.
Indeed, finance was a barrier described by both patients
and caregivers. Motivators for screening were similar
between the groups, and included a sense of self-empow-
erment and knowledge that treatment is available. This
study should provide a foundation for improved breast
health education and screening for earlier detection of the
disease.
Conclusions
Ultimate progress in the understanding and treatment of
breast cancer arises from basic and translational research
in many disciplines. Recent findings in progenitor cell
function and mammary development will contribute insight
to the consequences of the aberrant re-activation of devel-
opmental programs in many tumors. Research on basic
steroid hormone biology will ultimately add to the design
of hormone-based therapeutics. Understanding stromal–
epithelial interactions, and the behavior of particular onco-
genes and how they interact with various genetic anom-
alies in breast cancer, are also promising avenues to
molecular therapy. This conference provided a compre-
hensive collection of all of these approaches and should
foster fresh thinking and collaborations to achieve the
common goal.
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